Anyone Will Fund You on a Good Day
The real test of a lending partner shows up after the deal closes, not before. When I moved into private…
Junior capital refinances existing unitranche debt and supports continued de novo clinic growth
LOS ANGELES, September 9, 2026— Avante Capital Partners today announced it has provided $34.0 million in senior subordinated debt to a pediatric-focused dental service organization (the “Company”) in support of continued ownership by the Company’s private equity sponsor. The transaction refinances the Company’s existing unitranche debt and closed in June 2026.
The Company is a leading provider of pediatric dental care in its core markets, operating an integrated multi-specialty model that spans general pediatric dentistry, orthodontics, oral surgery, radiology, and specialty care. The sponsor’s ownership thesis centers on continuing to ramp and open new de novo clinics, expanding the Company’s footprint across existing and adjacent markets.
The transaction was originated through David Ng’s long-standing relationship with the sponsor’s deal team. Avante structured $34.0 million in senior subordinated debt to refinance the Company’s existing unitranche debt and support continued growth. Avante’s recent experience investing in other dental service organizations informed its underwriting and made the firm a natural capital partner for this transaction.
“This is exactly the kind of business we like to back: essential, recession-resilient services for an underserved population, run by a strong management team and Sponsor partner,” said David Ng, Managing Director at Avante Capital Partners.
Avante provides senior debt, unitranche, subordinated debt, and equity co-investment to companies generating roughly $3 million to $30 million in EBITDA, partnering with private equity firms, independent sponsors, and business owners across the United States. In this transaction, Avante’s junior capital was sized to support the Company’s long-term growth alongside its sponsor — flexible financing suited to a healthcare services platform navigating near-term volume dynamics while pursuing continued de novo expansion.
The information contained herein is for informational purposes only and should not be construed as investment advice. The views expressed are those of the author as of the date of publication and are subject to change without notice. Past performance is not indicative of future results.